TSE:ASP

Acerus Pharmaceuticals - ASP Stock Forecast, Price & News

C$0.36

0.00 (0.00%)

(As of 02/2/2023 12:00 AM ET)

Add

Compare

Today's Range: C$0.36
▼
C$0.36
50-Day Range: C$0.28
▼
C$1.29
52-Week Range: C$0.28
▼
C$10.00

Volume: N/A
Average Volume: 4,719 shs
Market Capitalization: C$2.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Acerus Pharmaceuticals (TSE:ASP) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Stock News Headlines

January 26, 2023 | finance.yahoo.com

IIROC Trading Halt - ASP

January 26, 2023 | finance.yahoo.com

Acerus Files For CCAA Protection

February 5, 2023 | Wall Street Watch Dogs (Ad)

“Future Fuel” will unleash $11 trillion wave of wealth

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

December 22, 2022 | finance.yahoo.com

Acerus Announces New Loan Agreement With First Generation Capital

November 18, 2022 | finance.yahoo.com

Acerus Pharmaceuticals Third Quarter 2022 Earnings: US$0.54 loss per share (vs US$0.64 loss in 3Q 2021)

August 3, 2022 | finance.yahoo.com

Acerus to Report Q2-2022 Financial Results and Host Investor Call

June 7, 2022 | finance.yahoo.com

Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders

May 10, 2022 | finance.yahoo.com

Acerus Reports First Quarter 2022 Financial Results

February 5, 2023 | Wall Street Watch Dogs (Ad)

“Future Fuel” will unleash $11 trillion wave of wealth

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

April 27, 2022 | finanznachrichten.de

Acerus Pharmaceuticals Corporation: Acerus Announces Completion of Share Consolidation

March 10, 2022 | ca.finance.yahoo.com

Stocks in play: Acerus Pharmaceuticals Corporation.

March 10, 2022 | finance.yahoo.com

Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call

February 18, 2022 | finance.yahoo.com

Acerus Announces Amendment to Loan Facilities

January 10, 2022 | finance.yahoo.com

Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico

December 13, 2021 | finance.yahoo.com

Acerus Announces Amendments to Loan Facilities

November 2, 2021 | finance.yahoo.com

Acerus to Report Q3-2021 Financial Results and Host Investor Call

October 26, 2021 | finance.yahoo.com

Research Reports Initiated on Healthcare Stocks Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen

September 9, 2021 | finance.yahoo.com

Even with Acerus Pharmaceuticals Corporation (TSE:ASP) stock down 11% this week, insiders who bought recently netted around US$102k

August 21, 2021 | barrons.com

Acerus Pharmaceuticals Corp.

August 12, 2021 | finance.yahoo.com

Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation

August 3, 2021 | finance.yahoo.com

Acerus to Report Q2-2021 Financial Results and Host Investor Call

July 12, 2021 | finance.yahoo.com

Acerus Provides Update on Litigation with Recipharm

June 29, 2021 | finance.yahoo.com

Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States

June 14, 2021 | finance.yahoo.com

Acerus Announces Voting Results for the 2021 Annual Meeting

June 10, 2021 | finance.yahoo.com

Acerus Pharmaceuticals'(TSE:ASP) Share Price Is Down 85% Over The Past Three Years.

June 2, 2021 | bloomberg.com

Acerus Pharmaceuticals Corp

May 13, 2021 | markets.businessinsider.com

Acerus Reports First Quarter 2021 Financial Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Company Calendar

Last Earnings: 11/14/2022
Today: 2/04/2023
Next Earnings (Estimated): 3/13/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:ASP
CUSIP: N/A
CIK: N/A
Web: www.aceruspharma.com
Phone: 416-679-0771
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 261.01
Current Ratio: 0.67
Quick Ratio: 0.26

Sales & Book Value

Annual Sales: C$3.04 million
Price / Sales: 0.91
Cash Flow: C$0.11 per share
Price / Cash Flow: 3.29
Book Value: C($1.80) per share
Price / Book: -0.20

Miscellaneous

Outstanding Shares: 7,708,000
Free Float: N/A
Market Cap: C$2.77 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Edward Gudaitis
Pres, CEO & Director

Mr. Gavin Damstra
Sr. VP of International Commercial

Dr. Christopher Sorli F.A.C.E.
M.D., Ph.D., Chief Medical Officer

Mr. Kevin Thomas Hickey
Sr. VP of US Commercial

Mr. Naveed Manzoor
Interim Chief Financial Officer

Mr. Chris Witty
Investor Relations

Mr. Philippe Savard
Sr. VP, Gen. Counsel & Corp. Sec.

Mr. Hubert Tomasz Czerwinski
Pres of Acerus Pharmaceuticals SRL

Key Competitors

View All Competitors

Insiders & Institutions

Edward Joseph Gudaitis
Bought 500 shares on 5/11/2022
Total: C$2,260.00 ($4.52/share)

View All Insider Transactions

ASP Stock - Frequently Asked Questions

How have ASP shares performed in 2023?: Acerus Pharmaceuticals' stock was trading at C$0.81 at the beginning of 2023. Since then, ASP shares have decreased by 55.6% and is now trading at C$0.36.
View the best growth stocks for 2023 here.
When is Acerus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ASP earnings forecast.
How were Acerus Pharmaceuticals' earnings last quarter?: Acerus Pharmaceuticals Co. (TSE:ASP) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.71) EPS for the quarter. The company had revenue of $1.01 million for the quarter.
What other stocks do shareholders of Acerus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Avid Bioservices (CDMO), OHR Pharmaceutical (OHRP), Trilogy International Partners (TRL), Absolute Software Co. (ABT.TO) (ABT), Ampliphi Biosciences (APHB) and Algonquin Power & Utilities (AQN).

What is Acerus Pharmaceuticals' stock symbol?: Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."
How do I buy shares of Acerus Pharmaceuticals?: Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Acerus Pharmaceuticals' stock price today?: One share of ASP stock can currently be purchased for approximately C$0.36.
How much money does Acerus Pharmaceuticals make?: Acerus Pharmaceuticals (TSE:ASP) has a market capitalization of C$2.77 million and generates C$3.04 million in revenue each year.
How can I contact Acerus Pharmaceuticals?: The official website for the company is www.aceruspharma.com. The company can be reached via phone at 416-679-0771.

This page (TSE:ASP) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial